Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) "CONDUCTOME"

Phase 1

Terminated

• Conditions: Cerebral Primitive Tumor With Chirurgical Indication
• Interventions: Other: MEG and MRI

• Registration Number: NCT02077504
• Lead Sponsor: University Hospital, Grenoble

Brief Summary

The purpose of this study is to determine the correlation between functional MEG analysis of the tumor and its periphery and the tumor stage and treatment response.

Detailed Description

A better tumor grade definition would provide an optimized surgical care, prognosis and therapeutical response evaluation.

Study Timeline

• Study Start: 2013-09
• Study First Submitted: 2013-09-18
• Study First Submitted QC: 2014-02-28
• Study First Posted: 2014-03-04
• Primary Completion: 2018-01-05
• Study Completion: 2018-01-05
• Status Verified: 2018-05
• Last Update Submitted: 2018-05-03
• Last Update Posted: 2018-05-09

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• more or equal than 18 years old
• patient affiliated to social security or similarly regime
• informed consent form signed
• supra-tentorial primitive cerebral tumor

Exclusion Criteria

• Pregnant women and lactating mothers
• Ward of court or under guardianship
• Adult unable to express their consent
• Person deprived of freedom by judicial or administrative decision
• Person hospitalized without their consent
• Person under legal protection
• Magnetic Resonance Imaging (MRI) contraindication (implanted material non MRI-compatible, ferro-magnetic foreign body, claustrophobia)
• Patients needed emergency medical care for other pathology
• severely altered general health (Performance Status 3 or 4)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CONDUCTOME	MEG and MRI	MEG and MRI

Primary Outcome Measures

Name	Time	Method
Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI) data in tumor grade prediction	1 week before exeresis
anatomopathologic and clinical data in tumor grade prediction	1 week after exeresis

Secondary Outcome Measures

Name	Time	Method
Measurement of molecules involved in glial cells neuralisation expression in tumor samples	Up to 1 month after surgery
Tumoral growth modelisation from patient MEG and MRI data	Up to 1 month after surgery

Trial Locations

Locations (1)

CLINATEC; 🇫🇷 Grenoble, France